Search research articles
Contact Us
Filters
Showing results (1-10 of 253) with videos related to
Page
of 26
Sort By:
Tumori
|
November 11, 2003
[Epoetin in cancer patients. Guidelines of the ASCO and the ASH for evidence-based clinical practice]
Lucia Del Mastro, ,
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2011
Temporary ovarian suppression with goserelin and ovarian function protection in patients with breast cancer undergoing chemotherapy
Lucia Del Mastro
Tumori
|
July 9, 2004
[The AIOM (Italian Association of Medical Oncology) practice guidelines for breast neoplasms]
Lucia Del Mastro, ,
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2017
Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer
Lucia Del Mastro
The Lancet. Oncology
|
September 7, 2013
Anthracycline-free therapy for HER2-amplified breast cancer
Alessandra Gennari, Lucia Del Mastro
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2006
Fertility preservation strategies for breast cancer patients
Lucia Del Mastro, Marco Venturini
Annals of Translational Medicine
|
April 3, 2023
Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
Simone Nardin, Lucia Del Mastro
Minerva Ginecologica
|
April 12, 2017
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients
Benedetta Conte, Lucia Del Mastro
Lancet (London, England)
|
April 7, 2005
ATAC trial update
Lucia Del Mastro, Marco Venturini
The Oncologist
|
October 15, 2015
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?
Lucia Del Mastro, Matteo Lambertini
Page
of 26
Search research articles
Search
Showing results (1-10 of 253) with videos related to
Sort By:
Page
of 26
Tumori
|
November 11, 2003
[Epoetin in cancer patients. Guidelines of the ASCO and the ASH for evidence-based clinical practice]
Lucia Del Mastro, ,
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2011
Temporary ovarian suppression with goserelin and ovarian function protection in patients with breast cancer undergoing chemotherapy
Lucia Del Mastro
Tumori
|
July 9, 2004
[The AIOM (Italian Association of Medical Oncology) practice guidelines for breast neoplasms]
Lucia Del Mastro, ,
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2017
Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer
Lucia Del Mastro
The Lancet. Oncology
|
September 7, 2013
Anthracycline-free therapy for HER2-amplified breast cancer
Alessandra Gennari, Lucia Del Mastro
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2006
Fertility preservation strategies for breast cancer patients
Lucia Del Mastro, Marco Venturini
Annals of Translational Medicine
|
April 3, 2023
Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
Simone Nardin, Lucia Del Mastro
Minerva Ginecologica
|
April 12, 2017
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients
Benedetta Conte, Lucia Del Mastro
Lancet (London, England)
|
April 7, 2005
ATAC trial update
Lucia Del Mastro, Marco Venturini
The Oncologist
|
October 15, 2015
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?
Lucia Del Mastro, Matteo Lambertini
Page
of 26